BMS Archive

Plant · Scientific monograph

Panax ginseng

Asian ginseng / Korean red ginseng

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Stress Response Research, Cognitive Function Research, Metabolic Research, Fatigue & Energy Research

Research overview

Historical use

Panax ginseng has been used in Traditional Chinese Medicine for over 2,000 years as a premier tonic herb ('ren shen' — man root), prescribed to restore vital energy (qi), strengthen the immune system, and extend longevity. Historical preparations included decoctions of dried root used for fatigue, cognitive decline, sexual dysfunction, and recovery from illness. Korean red ginseng — produced by steaming and drying — has been a distinct preparation valued for its enhanced ginsenoside profile and preserved since the Joseon dynasty.

Modern research context

Panax ginseng is among the world's most extensively studied adaptogens, with clinical evidence supporting its use in fatigue management, cognitive enhancement, metabolic regulation, and mood support. A 2026 randomised double-blind clinical trial demonstrated that 250 mg/day of ginseng extract significantly reduced cancer-related fatigue in gastrointestinal cancer survivors with excellent tolerability [3]. A 2026 randomised controlled crossover study found that ginseng consumed 90 minutes before a meal reduced postprandial glucose by 29% and insulin responses by 24% in healthy middle-aged adults [7]. Ginsenoside Rg1 shows multi-targeted pharmacological activity in neurodegenerative and metabolic disorders [6].

Adverse effects

Generally well tolerated at standard doses; no adverse events were reported in the 2026 cancer-fatigue RCT [3]. Common side effects at higher doses include insomnia, headache, agitation, GI upset, and hypertension ('ginseng abuse syndrome'). Hepatotoxicity has been documented with prolonged or high-dose use [5]. Oestrogenic effects reported in some case series; mastalgia and vaginal bleeding possible in postmenopausal women. Hypoglycaemia risk is clinically relevant given documented glucose-lowering effects [7].

Contraindications

Contraindicated with warfarin due to CYP2C9 interaction and antiplatelet activity. Avoid with MAO inhibitors due to stimulant and monoaminergic properties [2]. Caution in patients on antidiabetic medications due to additive glucose-lowering effects [7]. Avoid in hormonally sensitive conditions (oestrogen receptor-positive cancers). Use with caution in patients with hepatic impairment given documented hepatotoxicity risk [5]. Caution with statins and other CYP3A4 substrates [8].

Clinical and phytochemical data

Used part

Root (main and lateral rootlets); Korean red ginseng (steamed and dried root)

Primary active compounds

  • Ginsenoside Rg1 (protopanaxatriol-type)

  • Ginsenoside Rb1 (protopanaxadiol-type)

  • Ginsenoside Rc, Rd, Re, Rf

  • Compound K (active gut metabolite of protopanaxadiol ginsenosides)

  • Panaxans (polysaccharides)

  • Polyacetylenes (panaxynol, panaxydol)

Mechanism of action

Ginsenoside Rg1 exerts pleiotropic pharmacological effects through simultaneous modulation of NF-κB, MAPK, and Wnt/β-catenin signalling pathways, conferring anti-inflammatory, neuroprotective, and antifibrotic activity [6]. Panax ginseng modulates monoaminergic neurotransmission — including dopaminergic, serotonergic, and noradrenergic systems — and suppresses neuroinflammation and oxidative stress, providing a mechanistic basis for antidepressant and cognitive-enhancing effects [2]. Ginsenosides inhibit alpha-glucosidase and modulate GLUT4 translocation, contributing to clinically documented postprandial glucose reduction [7]. The ginsenoside metabolite targeting PRELID3B demonstrates selective anticancer activity in lung cancer cell lines [9]. Panax ginseng also modulates CYP1A2, CYP2C9, CYP2D6, and CYP3A4 enzyme activity, with implications for co-administered drug metabolism [1].

Pharmacokinetics

Absorption

Oral bioavailability of native ginsenosides is inherently low and highly variable due to poor intestinal membrane permeability and extensive pre-systemic metabolism [4]. Nano-formulation strategies have been developed specifically to overcome these bioavailability limitations and improve systemic circulation of ginsenoside compounds [4]. Ginsenoside Rg1 in particular demonstrates significant bioavailability limitations following standard oral dosing, which constrains therapeutic plasma concentrations [6]. Timing of administration relative to meals is clinically relevant: a 2026 RCT showed that a 90-minute preload produced significant glucose and insulin effects absent when the same dose was taken immediately before eating [7].

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Ginsenosides undergo extensive biotransformation by intestinal microbiota prior to absorption; the major active systemic metabolite in humans is Compound K (20-O-beta-(D-glucopyranosyl)-20(S)-protopanaxadiol), generated from protopanaxadiol-type ginsenosides. Protein binding and volume of distribution in humans have not been formally characterised for the major ginsenoside fractions.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Ginsenosides are primarily metabolised by intestinal bacterial enzymes (beta-glucosidases) to yield pharmacologically active aglycones and Compound K. Hepatic CYP450 enzymes — particularly CYP3A4 — contribute to further Phase I metabolism [1, 8]. Panax ginseng both inhibits and induces CYP450 isoforms (CYP1A2, CYP2C9, CYP2D6, CYP3A4) in a concentration- and constituent-dependent manner, introducing clinically significant variability in drug co-administration [1].

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Ginsenoside metabolites are eliminated primarily via renal and faecal routes following hepatic conjugation. Half-life values vary substantially across individual ginsenosides and have not been systematically characterised in a standardised human pharmacokinetic study available in the retrieved literature.

Safety and interactions

Drug interactions

CYP450 substrates (CYP1A2, CYP2C9, CYP2D6, CYP3A4): Panax ginseng modulates all four major CYP isoforms, with potential to raise or lower plasma levels of co-administered drugs depending on isoform and ginseng preparation [1]. Statins and antidiabetic drugs (CYP3A4 pathway): Ginseng-mediated CYP3A4 modulation can alter the pharmacokinetics of atorvastatin, simvastatin, and oral antidiabetic agents; monitoring is warranted [8]. Antidiabetic agents (insulin, sulfonylureas, metformin): Clinically documented additive glucose-lowering effect — 29% postprandial glucose reduction in RCT [7] — creates significant hypoglycaemia risk requiring dose adjustment. Antidepressants (SSRIs, SNRIs, MAO inhibitors): Potential pharmacodynamic interactions through shared monoaminergic mechanisms; avoid with MAO inhibitors [2]. Hepatotoxic medications: Additive hepatotoxicity risk documented with prolonged high-dose use of Panax ginseng; avoid combination with known hepatotoxins [5].

Toxicity

Generally well tolerated at therapeutic doses (250 mg/day) with no adverse events in a 2026 cancer population RCT [3]. Hepatotoxicity is documented with high-dose or prolonged use and constitutes the primary safety concern [5]. 'Ginseng abuse syndrome' (hypertension, insomnia, nervousness, morning diarrhoea) is reported with doses exceeding 3 g/day of crude root. Oestrogenic activity at high doses may precipitate hormonal adverse effects. LD50 data for standardised extracts in humans are not established.

Special precautions

Pregnancy

Insufficient human safety data. Animal studies raise concern for embryotoxicity at high doses. Avoid during pregnancy, particularly during the first trimester.

Lactation

Ginsenoside excretion into breast milk has not been characterised in humans. Avoid during lactation due to insufficient safety data.

Hepatic impairment

Hepatotoxicity risk is documented with high-dose use [5]; CYP450-mediated metabolism is hepatically dependent [1]. Use with caution in patients with pre-existing hepatic impairment; liver function monitoring is advisable.

Renal impairment

Ginsenoside metabolites are renally eliminated. Accumulation is possible in severe renal impairment. No formal dose adjustment guidelines are established; use caution and monitor.

Sources and references

  1. [1] - Shanaida M, Oleshchuk O, Shevchuk O et al., "Herbal Medicines and Drugs Interactions: Cytochrome P450 Responsibility", Current Medicinal Chemistry, 2026, PMID: 41764614
  2. [2] - Bertollo AG, Spohr L, Bearzi AE et al., "Medicinal Plants for Major Depressive Disorder", Brain Sciences, 2026, PMID: 41750223
  3. [3] - Rahmani A, Sanaat Z, Hassanzadeh HN et al., "The effect of ginseng extract on fatigue in cancer survivors: a randomized double-blind clinical trial", Supportive Care in Cancer, 2026, PMID: 41838185
  4. [4] - Tiwari P, Park KI, Mandal S, "Emerging Breakthroughs in Nano-Ginseng Innovations and Their Therapeutic Implications in Type 2 Diabetes", Pharmaceuticals, 2026, PMID: 41599783
  5. [5] - Frazer E, Zhao C, Lee J et al., "A Review of the Mechanisms and Risks of Panax ginseng in the Treatment of Alcohol Use Disorder", Diseases, 2025, PMID: 41002721
  6. [6] - Cortes H, Lima E, Duarte-Pena L et al., "Ginsenoside Rg1 as a Multifunctional Therapeutic Agent: Pharmacological Properties, Molecular Mechanisms and Clinical Perspectives", Food Science & Nutrition, 2026, PMID: 41648642
  7. [7] - Nilsson A, "Preload time-dependent effects of Panax ginseng on postprandial glucose tolerance: A randomized controlled study in healthy middle-aged participants", Frontiers in Nutrition, 2026, PMID: 41798830
  8. [8] - Hernandez-Lorca M, Timon IM, Ballester P et al., "Dietary Modulation of CYP3A4 and Its Impact on Statins and Antidiabetic Drugs: A Narrative Review", Pharmaceuticals, 2025, PMID: 41011221
  9. [9] - He J, Lok CN, Yang G et al., "A ginsenoside metabolite and its derivative target PRELID3B against lung cancer cells", Proceedings of the National Academy of Sciences, 2026, PMID: 42081720

Additional source links

Continue browsing